Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients [Estudio abierto para determinar la seguridad a largo plazo de la Safinamida en pacientes con enfermedad de Parkinson].
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Newron Pharmaceuticals; Newron Sweden AB
- 11 Aug 2012 Company (Newron Pharmaceuticals) added as reported by European Clinical Trials Database record.
- 30 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov record.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.